The first ever scientific publication of our MODAPLEX POLE/POLD1 Mutation Analysis Kit has been published! In early 2023 the publication was presented as a poster during that year’s ESMO congress and has now been accepted by a journal.
In the Saxon Network for Radionuclide Theranostics (SNRT), BIOTYPE joins forces with seven partners from science and industry to significantly shape progress in nuclear medicine through the evaluation of molecular biomarkers for patient stratification for therapy decisions and the development of new applications.
Dresden, 16 October 2023 - The "Gläserne Labor" (Transparent Laboratory) in Dresden is delighted to have received new equipment worth €16,800 as well as an additional cash donation of €2,500 for the purchase of further laboratory materials. The support for the extracurricular education programme comes from the Dresden-based molecular diagnostics company BIOTYPE and the Nordostchemie associations as part of the "Pro Chemieunterricht" campaign.
Dresden, 10.10.2023. Today, we had the privilege of hosting the Prime Minister of the Free State of Saxony, Mr. Michael Kretschmer. During the session, Wilhelm Zörgiebel and Norman Gerstner shared a captivating overview of the present advancements in molecular diagnostics and their crucial role in precision medicine.
Dresden, 27.09.2023. BIOTYPE presents a major upgrade of its MODAPLEX platform. The benchtop diagnostic platform for the fully integrated analysis of molecular biomarker signatures has been available since September 2023. With MODAPLEX, professional laboratories in research and clinical settings can now perform highly specialised molecular analyses quickly and easily in an automated manner.
We are delighted to announce the launch of our newest product: the QPCR POLE Mutation Analysis Kit!
BIOTYPE GmbH and STRATIFYER Molecular Pathology GmbH are pleased to announce their strategic collaboration aimed to develop innovative diagnostic tests to improve outcomes for patients with bladder cancer.
At this year's EHA2023 congress in Frankfurt, we presented a poster that was created in collaboration with the University Hospital Carl Gustav Carus, Dr. Anke Weber and Dr. Matthias Preussler.
We are excited to announce our new distribution partnership with Gencurix, Inc. for Germany. They are specialized in molecular cancer diagnostics and offer various ddPCR kits for detecting cancer mutations.
Our Tech Leads Dr. Christoph Schanzenbach and Dr. Matthias Preussler presented a poster titled "Syndromic testing for medium throughput in one workflow: flexible molecular analysis with the MODAPLEX platform" during the 10th Gene Quantification event #GQ2023 in Freising.
The first ever scientific publication of our MODAPLEX POLE/POLD1 Mutation Analysis Kit was presented during this year’s ESMO Gynaecological Cancers Congress in Barcelona!
We are thrilled about the designation of mdc medical device certification GmbH as the 9th EU-IVDR Notified Body.
We are pleased to announce that we have joined Scientist.com as a supplier to offer our contract development and manufacturing services! Scientist.com is the world's largest marketplace for medical research. The aim of the e-commerce platform is to connect researchers looking for custom services with providers from the life science industry.
The Molecular Diagnostics Group GmbH (MDG) and the Swiss company 4D Lifetec AG announce a strategic partnership to further industrialize the 4D Lifetest™ liquid biopsy assay.
Cardior Pharmaceuticals announced the CE marking of CardiorHealth miR-132 PCR kit which measures circulating microRNA-132 (miR-132) levels in the blood of heart failure patients following treatment with their lead candidate CDR132L. We are extremely proud that our biomarker assay development and manufacturing services have contributed to this success, and we look forward to continuing our cooperation.
NADMED established the first ever CE marked IVD assay for measuring NAD metabolites in human blood. This is a huge step forward in the healthcare industry to help patients worldwide! We are extremely proud that our services have contributed to this success, and we look forward to continuing our cooperation.
“Team Intelligence” behind Biotype’s Transformational Leadership
Transitioning into transformational leadership entails transformational changes. As Biotype is transforming and entering a new phase of development, it was vital for us to ensure that we decentralize decision making and adopt a more efficient approach.
We are delighted to announce that Biotype is entering a new phase of its corporate development with the appointment of Dr. Norman Gerstner as new CEO and Dr. Felix Zörgiebel as new CTO succeeding Dr. Karim Tabiti effective April 1, 2022.
07-10-2021
Biotype GmbH wins 1st place in the DNN Business Award 2020 offered by the Dresdner Neueste Nachrichten Verlag and the Ostsächsische Sparkasse Dresden.
28-06-2021
Biotechnology and medical technology companies based in Saxony made a significant contribution to combating the corona pandemic.
04-03-2021
New regulatory requirements are currently affecting the In-vitro diagnostic (IVD) industry with the transition from the In-vitro Diagnostic Directive (IVDD) to the In-vitro Diagnostic Regulation (IVDR).
05-12-2020
Biotype, together with a clinical cooperation partner, is right now developing a Modaplex panel to detect different genetic aberrations in one single run using synchronized PCR multiplex technologies.
02-04-2020
Biotype GmbH is commissioned to produce components for the Corona Virus COVID-19 genesig® Real-Time PCR Test by Primerdesign Ltd. A daily capacity of 8,000 to 10,000 tests is planned.
01-10-2019
Biotype launches 3 new assays on its molecular diagnostic platform ModaplexTM.
28-06-2019
We are excited to announce that Biotype Diagnostic GmbH and Biotype Innovation GmbH have decided to merge their capabilities to form one strong entity.
07-02-2019
Biotype expands highly specific CE-IVD portfolio for chimerism monitoring. 56 Mentype® DIPquant assays are now CE-IVD-registered.
14-12-2018
Within the InfectControl 2020 FINAR BMBF-project the selection for resistances is captured for the first time systematically by specialists coming from the fields of phytopathology, veterinary medicine and infection biology.
13-12-2018
SYNLAB Pharma, a subsidiary of SYNLAB Holding Deutschland GmbH announces that it has signed a collaboration agreement with Biotype with the intention to offer a Europe-wide clinical trial service for MSI and POLE/POLD1 mutation detection to indicate if patients harboring from GI cancer or EC would benefit from immune checkpoint inhibitor therapy.
01-06-2017
Since it was founded in 1999, Biotype Diagnostic GmbH has established an international position developing and marketing outstanding molecular diagnostics systems in the fields of forensics, dermatology and leukaemia. Another mainstay is producing complex testing systems commissioned by global players such as QIAGEN GmbH. Now, Biotype is extending its OEM business and exceptional skills in developing and producing made-to-order multiplex PCR assays in new fields.
14-03-2017
The new assays DigitalScreen/DigitalQuant of the Biotype Diagnostic GmbH ensure a robust and highly sensitive evaluation of disease progression after stem cell transplantation based on the innovative digital PCR technology.
23-02-2016
Quantitative Strategy for Chimerism Monitoring – new method provides significant increase in sensitivity by factor 20 which translates into massive time advantage
18-01-2016
50 molecular markers combined with highest sensitivity result in a dramatic improvement of chimerism monitoring
